What is the Clinical Role of Aerosolized Ribavirin?

Publisher Website
Google Scholar
Abstract
Aerosolized ribavirin is the first approved agent for the treatment of respiratory syncytial virus (RSV) infection. However, the clinical use of ribavirin is controversial. Although ribavirin-treated patients appear to be subjectively improved, the benefit in terms of decreased morbidity and mortality is not well established. Furthermore, the drug has been found to be teratogenic, carcinogenic, and mutagenic, depending upon the scientific model. Because of its unique mode of administration, environmental exposure of healthcare personnel and other patients may occur. Although administration in mechanically ventilated patients decreases the amount of ribavirin liberated into the atmosphere, the drug crystallizes in the endotracheal tube, occasionally resulting in reduced ventilation. The lack of data documenting efficacy and the above environmental concerns result in difficult decisions for hospitals. Further studies are necessary to clarify the value and safety of ribavirin in the treatment of RSV infection.